AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
methyl nicotinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3355 | 93-60-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
erythema provoked is basis of a methylnicotinate test of anti-inflammatories
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 68 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.885 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.153 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 60.954 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 75.162 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 74.210 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 76.600 | % | High | 1 |
| herg | hERG pIC50 | 3.749 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 168.267 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 61.944 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 61.700 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PAK4,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK | 45 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,DYRK1B,GRK2,PRKDC | 6 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.650 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 276.694 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 81.190 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.183 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 68.180 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 49.431 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 95.540 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 70.050 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 3.819 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:25212 | metabolite |
| CHEBI has role | CHEBI:33231 | antitubercular agent |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:35679 | antilipemic drug |
| CHEBI has role | CHEBI:35821 | anticholesteremic drug |
| CHEBI has role | CHEBI:50247 | antidote |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:76924 | plant metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:84087 | human urinary metabolite |
| CHEBI has role | CHEBI:84264 | EC 3.5.1.19 (nicotinamidase) inhibitor |
| CHEBI has role | CHEBI:145947 | antiatherosclerotic agent |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Joint pain | indication | 57676002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.01 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4020266 | VUID |
| N0000179190 | NUI |
| D04991 | KEGG_DRUG |
| 4017661 | VANDF |
| 4019440 | VANDF |
| 4020266 | VANDF |
| C0066412 | UMLSCUI |
| CHEBI:134761 | CHEBI |
| NIO | PDB_CHEM_ID |
| CHEMBL379845 | ChEMBL_ID |
| 7151 | PUBCHEM_CID |
| DB13882 | DRUGBANK_ID |
| C008473 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7B1AVU9DJN | UNII |
| 29900 | RXNORM |
| 15230 | MMSL |
| 2275 | MMSL |
| 43641 | MMSL |
| 5169 | MMSL |
| 7161 | MMSL |
| NOCODE | MMSL |
| d00314 | MMSL |
| 001052 | NDDF |
| 001987 | NDDF |
| 273943001 | SNOMEDCT_US |
| 424803001 | SNOMEDCT_US |
| 425096006 | SNOMEDCT_US |
| 63639004 | SNOMEDCT_US |
| C0027996 | UMLSCUI |
| DB00627 | DRUGBANK_ID |
| 938 | PUBCHEM_CID |
| CHEBI:15940 | CHEBI |
| 7B1AVU9DJN | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Arth Arrest | HUMAN OTC DRUG LABEL | 2 | 76018-100 | CREAM | 0.50 g | TOPICAL | OTC Monograph Drug | 9 sections |
| Arth RX Topical Analgesic | HUMAN OTC DRUG LABEL | 2 | 76069-100 | LOTION | 0.50 g | TOPICAL | OTC Monograph Drug | 11 sections |
| Nuvira | HUMAN OTC DRUG LABEL | 4 | 83295-3313 | PATCH | 0.00 g | CUTANEOUS | OTC Monograph Drug | 14 sections |